TW200412241A - Pharmaceutical uses for alpha2delta ligands - Google Patents

Info

Publication number

TW200412241A

TW200412241A TW092135260A TW92135260A TW200412241A TW 200412241 A TW200412241 A TW 200412241A TW 092135260 A TW092135260 A TW 092135260A TW 92135260 A TW92135260 A TW 92135260A TW 200412241 A TW200412241 A TW 200412241A

Authority

TW

Taiwan

Prior art keywords

pain

aminomethyl

disorders

disease

methyl

Prior art date

2002-12-13

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003446 ligand Substances 0.000 title claims abstract description 37
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 99
• 150000003839 salts Chemical class 0.000 claims abstract description 93
• 238000000034 method Methods 0.000 claims abstract description 77
• 201000010099 disease Diseases 0.000 claims description 78
• 208000002193 Pain Diseases 0.000 claims description 74
• 241000124008 Mammalia Species 0.000 claims description 44
• 208000024891 symptom Diseases 0.000 claims description 34
• 238000011282 treatment Methods 0.000 claims description 26
• 230000005856 abnormality Effects 0.000 claims description 25
• 239000000203 mixture Substances 0.000 claims description 25
• 229930182470 glycoside Natural products 0.000 claims description 24
• 150000002338 glycosides Chemical class 0.000 claims description 24
• 208000011580 syndromic disease Diseases 0.000 claims description 23
• 239000003814 drug Substances 0.000 claims description 20
• 230000002159 abnormal effect Effects 0.000 claims description 19
• 208000020016 psychiatric disease Diseases 0.000 claims description 19
• 229940079593 drug Drugs 0.000 claims description 18
• 208000003251 Pruritus Diseases 0.000 claims description 17
• 208000019901 Anxiety disease Diseases 0.000 claims description 16
• 208000004296 neuralgia Diseases 0.000 claims description 16
• 208000035475 disorder Diseases 0.000 claims description 15
• 230000001154 acute effect Effects 0.000 claims description 14
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 239000000126 substance Substances 0.000 claims description 12
• 201000006549 dyspepsia Diseases 0.000 claims description 11
• 208000014674 injury Diseases 0.000 claims description 11
• 206010022437 insomnia Diseases 0.000 claims description 11
• 230000007803 itching Effects 0.000 claims description 11
• 230000001225 therapeutic effect Effects 0.000 claims description 11
• 208000018737 Parkinson disease Diseases 0.000 claims description 10
• 238000002512 chemotherapy Methods 0.000 claims description 10
• 206010012289 Dementia Diseases 0.000 claims description 9
• 201000001119 neuropathy Diseases 0.000 claims description 9
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
• 230000007958 sleep Effects 0.000 claims description 9
• 208000024827 Alzheimer disease Diseases 0.000 claims description 8
• 206010033799 Paralysis Diseases 0.000 claims description 8
• 230000036506 anxiety Effects 0.000 claims description 8
• 208000012661 Dyskinesia Diseases 0.000 claims description 7
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
• 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
• 208000028017 Psychotic disease Diseases 0.000 claims description 7
• 230000001684 chronic effect Effects 0.000 claims description 7
• 230000006378 damage Effects 0.000 claims description 7
• 230000002981 neuropathic effect Effects 0.000 claims description 7
• 230000035882 stress Effects 0.000 claims description 7
• 208000011117 substance-related disease Diseases 0.000 claims description 7
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 6
• 208000027534 Emotional disease Diseases 0.000 claims description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
• 206010020853 Hypertonic bladder Diseases 0.000 claims description 6
• 206010061218 Inflammation Diseases 0.000 claims description 6
• 208000019695 Migraine disease Diseases 0.000 claims description 6
• 206010028980 Neoplasm Diseases 0.000 claims description 6
• 206010068106 Occipital neuralgia Diseases 0.000 claims description 6
• 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 6
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 6
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 6
• 206010047700 Vomiting Diseases 0.000 claims description 6
• 206010008118 cerebral infarction Diseases 0.000 claims description 6
• 230000000694 effects Effects 0.000 claims description 6
• 230000004054 inflammatory process Effects 0.000 claims description 6
• 230000007823 neuropathy Effects 0.000 claims description 6
• 208000020629 overactive bladder Diseases 0.000 claims description 6
• 210000000278 spinal cord Anatomy 0.000 claims description 6
• 230000008733 trauma Effects 0.000 claims description 6
• 230000008673 vomiting Effects 0.000 claims description 6
• SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 5
• 206010010904 Convulsion Diseases 0.000 claims description 5
• 206010011224 Cough Diseases 0.000 claims description 5
• 241001465754 Metazoa Species 0.000 claims description 5
• 208000027418 Wounds and injury Diseases 0.000 claims description 5
• 230000003542 behavioural effect Effects 0.000 claims description 5
• 230000002490 cerebral effect Effects 0.000 claims description 5
• 230000003001 depressive effect Effects 0.000 claims description 5
• 206010015037 epilepsy Diseases 0.000 claims description 5
• 208000024798 heartburn Diseases 0.000 claims description 5
• 206010027599 migraine Diseases 0.000 claims description 5
• 201000003631 narcolepsy Diseases 0.000 claims description 5
• 210000005036 nerve Anatomy 0.000 claims description 5
• 208000004998 Abdominal Pain Diseases 0.000 claims description 4
• 206010002383 Angina Pectoris Diseases 0.000 claims description 4
• 208000020925 Bipolar disease Diseases 0.000 claims description 4
• 201000006474 Brain Ischemia Diseases 0.000 claims description 4
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
• 206010008748 Chorea Diseases 0.000 claims description 4
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 4
• 206010010741 Conjunctivitis Diseases 0.000 claims description 4
• 208000011231 Crohn disease Diseases 0.000 claims description 4
• 206010063057 Cystitis noninfective Diseases 0.000 claims description 4
• 201000004624 Dermatitis Diseases 0.000 claims description 4
• 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
• 208000001640 Fibromyalgia Diseases 0.000 claims description 4
• 206010019196 Head injury Diseases 0.000 claims description 4
• 208000023105 Huntington disease Diseases 0.000 claims description 4
• 206010020751 Hypersensitivity Diseases 0.000 claims description 4
• 206010021143 Hypoxia Diseases 0.000 claims description 4
• 208000005890 Neuroma Diseases 0.000 claims description 4
• 208000008469 Peptic Ulcer Diseases 0.000 claims description 4
• 206010034912 Phobia Diseases 0.000 claims description 4
• 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 4
• 206010039710 Scleroderma Diseases 0.000 claims description 4
• 208000034972 Sudden Infant Death Diseases 0.000 claims description 4
• 206010042440 Sudden infant death syndrome Diseases 0.000 claims description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
• 206010047163 Vasospasm Diseases 0.000 claims description 4
• 208000026935 allergic disease Diseases 0.000 claims description 4
• 208000022531 anorexia Diseases 0.000 claims description 4
• 206010003119 arrhythmia Diseases 0.000 claims description 4
• 230000006793 arrhythmia Effects 0.000 claims description 4
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
• 201000003139 chronic cystitis Diseases 0.000 claims description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
• 206010061428 decreased appetite Diseases 0.000 claims description 4
• 208000002173 dizziness Diseases 0.000 claims description 4
• 208000026278 immune system disease Diseases 0.000 claims description 4
• 208000015181 infectious disease Diseases 0.000 claims description 4
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
• 208000028867 ischemia Diseases 0.000 claims description 4
• 230000000302 ischemic effect Effects 0.000 claims description 4
• 201000003152 motion sickness Diseases 0.000 claims description 4
• 230000000926 neurological effect Effects 0.000 claims description 4
• 201000008482 osteoarthritis Diseases 0.000 claims description 4
• 208000019899 phobic disease Diseases 0.000 claims description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
• 201000000980 schizophrenia Diseases 0.000 claims description 4
• 208000012672 seasonal affective disease Diseases 0.000 claims description 4
• 230000001568 sexual effect Effects 0.000 claims description 4
• 238000001356 surgical procedure Methods 0.000 claims description 4
• 238000002560 therapeutic procedure Methods 0.000 claims description 4
• 230000002792 vascular Effects 0.000 claims description 4
• 230000024883 vasodilation Effects 0.000 claims description 4
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
• 206010007710 Cartilage injury Diseases 0.000 claims description 3
• 206010012335 Dependence Diseases 0.000 claims description 3
• 206010014950 Eosinophilia Diseases 0.000 claims description 3
• 208000004547 Hallucinations Diseases 0.000 claims description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
• 206010049949 Intercostal neuralgia Diseases 0.000 claims description 3
• 208000008930 Low Back Pain Diseases 0.000 claims description 3
• 208000003782 Raynaud disease Diseases 0.000 claims description 3
• 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
• 208000005793 Restless legs syndrome Diseases 0.000 claims description 3
• 206010039897 Sedation Diseases 0.000 claims description 3
• 206010040744 Sinus headache Diseases 0.000 claims description 3
• 208000004557 Vasovagal Syncope Diseases 0.000 claims description 3
• 238000002266 amputation Methods 0.000 claims description 3
• 230000006399 behavior Effects 0.000 claims description 3
• 210000003461 brachial plexus Anatomy 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 claims description 3
• 210000003169 central nervous system Anatomy 0.000 claims description 3
• 208000012601 choreatic disease Diseases 0.000 claims description 3
• 238000007906 compression Methods 0.000 claims description 3
• 230000006835 compression Effects 0.000 claims description 3
• 230000036461 convulsion Effects 0.000 claims description 3
• 230000002920 convulsive effect Effects 0.000 claims description 3
• 235000005911 diet Nutrition 0.000 claims description 3
• 230000037213 diet Effects 0.000 claims description 3
• 230000003176 fibrotic effect Effects 0.000 claims description 3
• 230000006870 function Effects 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 230000033001 locomotion Effects 0.000 claims description 3
• 201000006417 multiple sclerosis Diseases 0.000 claims description 3
• 230000008693 nausea Effects 0.000 claims description 3
• 230000001314 paroxysmal effect Effects 0.000 claims description 3
• 230000002093 peripheral effect Effects 0.000 claims description 3
• 230000035935 pregnancy Effects 0.000 claims description 3
• 230000002028 premature Effects 0.000 claims description 3
• 230000005855 radiation Effects 0.000 claims description 3
• 230000037322 slow-wave sleep Effects 0.000 claims description 3
• 201000009032 substance abuse Diseases 0.000 claims description 3
• 206010042772 syncope Diseases 0.000 claims description 3
• 208000004371 toothache Diseases 0.000 claims description 3
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 2
• 208000000187 Abnormal Reflex Diseases 0.000 claims description 2
• 206010002153 Anal fissure Diseases 0.000 claims description 2
• 206010002820 Antisocial behaviour Diseases 0.000 claims description 2
• 208000016583 Anus disease Diseases 0.000 claims description 2
• 208000006820 Arthralgia Diseases 0.000 claims description 2
• 206010003497 Asphyxia Diseases 0.000 claims description 2
• 206010003805 Autism Diseases 0.000 claims description 2
• 208000020706 Autistic disease Diseases 0.000 claims description 2
• 208000000412 Avitaminosis Diseases 0.000 claims description 2
• 208000037157 Azotemia Diseases 0.000 claims description 2
• 208000035143 Bacterial infection Diseases 0.000 claims description 2
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
• 241000283690 Bos taurus Species 0.000 claims description 2
• 206010048962 Brain oedema Diseases 0.000 claims description 2
• 208000026310 Breast neoplasm Diseases 0.000 claims description 2
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 241000282472 Canis lupus familiaris Species 0.000 claims description 2
• 208000000094 Chronic Pain Diseases 0.000 claims description 2
• 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 2
• 208000034656 Contusions Diseases 0.000 claims description 2
• 206010011026 Corneal lesion Diseases 0.000 claims description 2
• 102000004127 Cytokines Human genes 0.000 claims description 2
• 108090000695 Cytokines Proteins 0.000 claims description 2
• 208000019505 Deglutition disease Diseases 0.000 claims description 2
• 206010012239 Delusion Diseases 0.000 claims description 2
• 208000024254 Delusional disease Diseases 0.000 claims description 2
• 208000016192 Demyelinating disease Diseases 0.000 claims description 2
• 208000020401 Depressive disease Diseases 0.000 claims description 2
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
• 206010012442 Dermatitis contact Diseases 0.000 claims description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
• 208000025967 Dissociative Identity disease Diseases 0.000 claims description 2
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
• 206010014498 Embolic stroke Diseases 0.000 claims description 2
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
• 206010015866 Extravasation Diseases 0.000 claims description 2
• 206010015958 Eye pain Diseases 0.000 claims description 2
• 208000009531 Fissure in Ano Diseases 0.000 claims description 2
• 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
• 208000007882 Gastritis Diseases 0.000 claims description 2
• 206010017886 Gastroduodenal ulcer Diseases 0.000 claims description 2
• 201000005569 Gout Diseases 0.000 claims description 2
• 102000018997 Growth Hormone Human genes 0.000 claims description 2
• 108010051696 Growth Hormone Proteins 0.000 claims description 2
• 206010019233 Headaches Diseases 0.000 claims description 2
• 241000590002 Helicobacter pylori Species 0.000 claims description 2
• 208000033830 Hot Flashes Diseases 0.000 claims description 2
• 206010060800 Hot flush Diseases 0.000 claims description 2
• 208000004454 Hyperalgesia Diseases 0.000 claims description 2
• 206010020601 Hyperchlorhydria Diseases 0.000 claims description 2
• 208000035154 Hyperesthesia Diseases 0.000 claims description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
• 206010020772 Hypertension Diseases 0.000 claims description 2
• 206010021135 Hypovitaminosis Diseases 0.000 claims description 2
• 206010021639 Incontinence Diseases 0.000 claims description 2
• 206010022998 Irritability Diseases 0.000 claims description 2
• 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
• 206010058031 Joint adhesion Diseases 0.000 claims description 2
• 208000012659 Joint disease Diseases 0.000 claims description 2
• 206010025323 Lymphomas Diseases 0.000 claims description 2
• 206010026749 Mania Diseases 0.000 claims description 2
• 208000027530 Meniere disease Diseases 0.000 claims description 2
• 206010053236 Mixed incontinence Diseases 0.000 claims description 2
• 208000019022 Mood disease Diseases 0.000 claims description 2
• 206010028293 Muscle contractions involuntary Diseases 0.000 claims description 2
• 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
• 208000000112 Myalgia Diseases 0.000 claims description 2
• 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
• 206010028813 Nausea Diseases 0.000 claims description 2
• 206010028817 Nausea and vomiting symptoms Diseases 0.000 claims description 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
• 206010034158 Pathological gambling Diseases 0.000 claims description 2
• 241001494479 Pecora Species 0.000 claims description 2
• CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims description 2
• 208000004983 Phantom Limb Diseases 0.000 claims description 2
• 206010056238 Phantom pain Diseases 0.000 claims description 2
• 208000005374 Poisoning Diseases 0.000 claims description 2
• 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 claims description 2
• 206010066963 Procedural vomiting Diseases 0.000 claims description 2
• 206010036774 Proctitis Diseases 0.000 claims description 2
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 claims description 2
• 208000029808 Psychomotor disease Diseases 0.000 claims description 2
• 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 2
• 206010037660 Pyrexia Diseases 0.000 claims description 2
• 206010038743 Restlessness Diseases 0.000 claims description 2
• 206010049002 Scar pain Diseases 0.000 claims description 2
• 208000024791 Schizotypal Personality disease Diseases 0.000 claims description 2
• 208000008765 Sciatica Diseases 0.000 claims description 2
• 208000034189 Sclerosis Diseases 0.000 claims description 2
• 201000000552 Scott syndrome Diseases 0.000 claims description 2
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
• 208000010340 Sleep Deprivation Diseases 0.000 claims description 2
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
• 206010041235 Snoring Diseases 0.000 claims description 2
• 206010041250 Social phobia Diseases 0.000 claims description 2
• 206010041347 Somnambulism Diseases 0.000 claims description 2
• 201000002661 Spondylitis Diseases 0.000 claims description 2
• 208000010040 Sprains and Strains Diseases 0.000 claims description 2
• 208000006011 Stroke Diseases 0.000 claims description 2
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
• 241000282887 Suidae Species 0.000 claims description 2
• 206010042496 Sunburn Diseases 0.000 claims description 2
• 206010066371 Tendon pain Diseases 0.000 claims description 2
• 206010043269 Tension headache Diseases 0.000 claims description 2
• 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
• 206010044565 Tremor Diseases 0.000 claims description 2
• 206010046477 Urethral syndrome Diseases 0.000 claims description 2
• 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 2
• 206010046543 Urinary incontinence Diseases 0.000 claims description 2
• 206010064921 Urinary tract inflammation Diseases 0.000 claims description 2
• 208000001407 Vascular Headaches Diseases 0.000 claims description 2
• 201000004810 Vascular dementia Diseases 0.000 claims description 2
• 206010047115 Vasculitis Diseases 0.000 claims description 2
• 208000036142 Viral infection Diseases 0.000 claims description 2
• 229940025084 amphetamine Drugs 0.000 claims description 2
• 238000002583 angiography Methods 0.000 claims description 2
• 201000002426 animal phobia Diseases 0.000 claims description 2
• 208000024823 antisocial personality disease Diseases 0.000 claims description 2
• 239000002249 anxiolytic agent Substances 0.000 claims description 2
• 230000000949 anxiolytic effect Effects 0.000 claims description 2
• 201000008937 atopic dermatitis Diseases 0.000 claims description 2
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
• 208000028683 bipolar I disease Diseases 0.000 claims description 2
• 208000025307 bipolar depression Diseases 0.000 claims description 2
• 230000017531 blood circulation Effects 0.000 claims description 2
• 210000000988 bone and bone Anatomy 0.000 claims description 2
• 208000030963 borderline personality disease Diseases 0.000 claims description 2
• 208000006752 brain edema Diseases 0.000 claims description 2
• 210000000133 brain stem Anatomy 0.000 claims description 2
• 210000005252 bulbus oculi Anatomy 0.000 claims description 2
• 230000000747 cardiac effect Effects 0.000 claims description 2
• 210000001326 carotid sinus Anatomy 0.000 claims description 2
• 210000004027 cell Anatomy 0.000 claims description 2
• 230000004663 cell proliferation Effects 0.000 claims description 2
• 230000035606 childbirth Effects 0.000 claims description 2
• 229960003920 cocaine Drugs 0.000 claims description 2
• 206010009887 colitis Diseases 0.000 claims description 2
• 208000010247 contact dermatitis Diseases 0.000 claims description 2
• 230000008602 contraction Effects 0.000 claims description 2
• 201000003146 cystitis Diseases 0.000 claims description 2
• 230000003111 delayed effect Effects 0.000 claims description 2
• 231100000868 delusion Toxicity 0.000 claims description 2
• 238000001784 detoxification Methods 0.000 claims description 2
• 230000004064 dysfunction Effects 0.000 claims description 2
• 230000036251 extravasation Effects 0.000 claims description 2
• 210000001508 eye Anatomy 0.000 claims description 2
• 208000030533 eye disease Diseases 0.000 claims description 2
• 235000013305 food Nutrition 0.000 claims description 2
• 208000001130 gallstones Diseases 0.000 claims description 2
• 210000004211 gastric acid Anatomy 0.000 claims description 2
• 201000011587 gastric lymphoma Diseases 0.000 claims description 2
• 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 2
• 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
• 239000000122 growth hormone Substances 0.000 claims description 2
• 231100000869 headache Toxicity 0.000 claims description 2
• 229940037467 helicobacter pylori Drugs 0.000 claims description 2
• 230000011132 hemopoiesis Effects 0.000 claims description 2
• 208000006454 hepatitis Diseases 0.000 claims description 2
• 231100000283 hepatitis Toxicity 0.000 claims description 2
• 206010020745 hyperreflexia Diseases 0.000 claims description 2
• 230000035859 hyperreflexia Effects 0.000 claims description 2
• 208000003532 hypothyroidism Diseases 0.000 claims description 2
• 230000002989 hypothyroidism Effects 0.000 claims description 2
• 208000018875 hypoxemia Diseases 0.000 claims description 2
• 230000007954 hypoxia Effects 0.000 claims description 2
• 201000001881 impotence Diseases 0.000 claims description 2
• 206010021654 increased appetite Diseases 0.000 claims description 2
• 208000000509 infertility Diseases 0.000 claims description 2
• 230000036512 infertility Effects 0.000 claims description 2
• 231100000535 infertility Toxicity 0.000 claims description 2
• 230000003993 interaction Effects 0.000 claims description 2
• 238000007917 intracranial administration Methods 0.000 claims description 2
• 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 2
• 230000003211 malignant effect Effects 0.000 claims description 2
• 240000004308 marijuana Species 0.000 claims description 2
• 239000000463 material Substances 0.000 claims description 2
• 206010027175 memory impairment Diseases 0.000 claims description 2
• 230000003340 mental effect Effects 0.000 claims description 2
• 206010052787 migraine without aura Diseases 0.000 claims description 2
• 208000013465 muscle pain Diseases 0.000 claims description 2
• 230000014399 negative regulation of angiogenesis Effects 0.000 claims description 2
• 229960002715 nicotine Drugs 0.000 claims description 2
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
• 230000000422 nocturnal effect Effects 0.000 claims description 2
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
• 208000011906 peptic ulcer disease Diseases 0.000 claims description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
• 208000030062 persistent idiopathic facial pain Diseases 0.000 claims description 2
• 239000006187 pill Substances 0.000 claims description 2
• 231100000572 poisoning Toxicity 0.000 claims description 2
• 230000000607 poisoning effect Effects 0.000 claims description 2
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
• 230000002980 postoperative effect Effects 0.000 claims description 2
• 239000003380 propellant Substances 0.000 claims description 2
• 230000001107 psychogenic effect Effects 0.000 claims description 2
• 230000008430 psychophysiology Effects 0.000 claims description 2
• 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims description 2
• 230000000306 recurrent effect Effects 0.000 claims description 2
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
• 238000010008 shearing Methods 0.000 claims description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
• 210000004872 soft tissue Anatomy 0.000 claims description 2
• 201000001716 specific phobia Diseases 0.000 claims description 2
• 239000007921 spray Substances 0.000 claims description 2
• 208000003265 stomatitis Diseases 0.000 claims description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
• 239000003053 toxin Substances 0.000 claims description 2
• 231100000765 toxin Toxicity 0.000 claims description 2
• 108700012359 toxins Proteins 0.000 claims description 2
• 230000001052 transient effect Effects 0.000 claims description 2
• 208000009852 uremia Diseases 0.000 claims description 2
• 208000027491 vestibular disease Diseases 0.000 claims description 2
• 230000003612 virological effect Effects 0.000 claims description 2
• 230000009278 visceral effect Effects 0.000 claims description 2
• 208000009935 visceral pain Diseases 0.000 claims description 2
• 208000030401 vitamin deficiency disease Diseases 0.000 claims description 2
• 208000016261 weight loss Diseases 0.000 claims description 2
• 230000004580 weight loss Effects 0.000 claims description 2
• KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims 2
• 206010003791 Aura Diseases 0.000 claims 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
• 201000004681 Psoriasis Diseases 0.000 claims 2
• 208000005392 Spasm Diseases 0.000 claims 2
• 206010003246 arthritis Diseases 0.000 claims 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
• 210000003205 muscle Anatomy 0.000 claims 2
• 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
• 238000007631 vascular surgery Methods 0.000 claims 2
• 208000007848 Alcoholism Diseases 0.000 claims 1
• 241000790908 Arachnitis Species 0.000 claims 1
• 208000036487 Arthropathies Diseases 0.000 claims 1
• 240000008564 Boehmeria nivea Species 0.000 claims 1
• 208000010392 Bone Fractures Diseases 0.000 claims 1
• 206010051290 Central nervous system lesion Diseases 0.000 claims 1
• 206010068631 Childhood depression Diseases 0.000 claims 1
• 208000027932 Collagen disease Diseases 0.000 claims 1
• 206010010071 Coma Diseases 0.000 claims 1
• 206010012374 Depressed mood Diseases 0.000 claims 1
• 201000009273 Endometriosis Diseases 0.000 claims 1
• 208000010201 Exanthema Diseases 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 241000287828 Gallus gallus Species 0.000 claims 1
• 206010024264 Lethargy Diseases 0.000 claims 1
• 208000036626 Mental retardation Diseases 0.000 claims 1
• 208000021908 Myocardial disease Diseases 0.000 claims 1
• 206010061310 Nerve root injury Diseases 0.000 claims 1
• 208000004550 Postoperative Pain Diseases 0.000 claims 1
• 241000219780 Pueraria Species 0.000 claims 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
• 208000010798 Tongue disease Diseases 0.000 claims 1
• 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
• 208000026345 acute stress disease Diseases 0.000 claims 1
• 229940005530 anxiolytics Drugs 0.000 claims 1
• 206010003074 arachnoiditis Diseases 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 230000002567 autonomic effect Effects 0.000 claims 1
• 210000000481 breast Anatomy 0.000 claims 1
• 238000013172 carotid endarterectomy Methods 0.000 claims 1
• 235000013330 chicken meat Nutrition 0.000 claims 1
• 230000001149 cognitive effect Effects 0.000 claims 1
• 230000009519 contusion Effects 0.000 claims 1
• 230000009547 development abnormality Effects 0.000 claims 1
• 230000009266 disease activity Effects 0.000 claims 1
• 208000001848 dysentery Diseases 0.000 claims 1
• 230000002996 emotional effect Effects 0.000 claims 1
• 201000005884 exanthem Diseases 0.000 claims 1
• 206010016256 fatigue Diseases 0.000 claims 1
• 230000004761 fibrosis Effects 0.000 claims 1
• 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
• 238000001631 haemodialysis Methods 0.000 claims 1
• 230000003394 haemopoietic effect Effects 0.000 claims 1
• 239000000380 hallucinogen Substances 0.000 claims 1
• 230000000322 hemodialysis Effects 0.000 claims 1
• 210000004276 hyalin Anatomy 0.000 claims 1
• 208000013602 lip disease Diseases 0.000 claims 1
• 230000014759 maintenance of location Effects 0.000 claims 1
• 210000004086 maxillary sinus Anatomy 0.000 claims 1
• 210000002500 microbody Anatomy 0.000 claims 1
• 229960005181 morphine Drugs 0.000 claims 1
• 201000000585 muscular atrophy Diseases 0.000 claims 1
• 230000001537 neural effect Effects 0.000 claims 1
• 231100000862 numbness Toxicity 0.000 claims 1
• 238000011275 oncology therapy Methods 0.000 claims 1
• 208000028169 periodontal disease Diseases 0.000 claims 1
• FHSWXOCOMAVQKE-UHFFFAOYSA-N phenylazanium;acetate Chemical compound CC([O-])=O.[NH3+]C1=CC=CC=C1 FHSWXOCOMAVQKE-UHFFFAOYSA-N 0.000 claims 1
• 206010037844 rash Diseases 0.000 claims 1
• 230000000276 sedentary effect Effects 0.000 claims 1
• 201000002859 sleep apnea Diseases 0.000 claims 1
• 230000003860 sleep quality Effects 0.000 claims 1
• 201000006152 substance dependence Diseases 0.000 claims 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
• 229960003495 thiamine Drugs 0.000 claims 1
• 235000019157 thiamine Nutrition 0.000 claims 1
• 239000011721 thiamine Substances 0.000 claims 1
• 229940098465 tincture Drugs 0.000 claims 1
• 239000003204 tranquilizing agent Substances 0.000 claims 1
• 230000002936 tranquilizing effect Effects 0.000 claims 1
• 230000009529 traumatic brain injury Effects 0.000 claims 1
• 150000001875 compounds Chemical class 0.000 abstract description 98
• 125000000217 alkyl group Chemical group 0.000 abstract description 43
• 239000001257 hydrogen Substances 0.000 abstract description 18
• 229910052739 hydrogen Inorganic materials 0.000 abstract description 18
• 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 4
• 208000015114 central nervous system disease Diseases 0.000 abstract 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 318
• -1 cyclic amino acid compound Chemical class 0.000 description 98
• 239000002253 acid Substances 0.000 description 43
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 27
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 25
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 22
• 235000011054 acetic acid Nutrition 0.000 description 21
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
• 238000007792 addition Methods 0.000 description 17
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 17
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 15
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 15
• 229910052799 carbon Inorganic materials 0.000 description 14
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 14
• 125000001424 substituent group Chemical group 0.000 description 14
• 125000004429 atom Chemical group 0.000 description 12
• MHPUGCYGQWGLJL-UHFFFAOYSA-N 5-methyl-hexanoic acid Chemical compound CC(C)CCCC(O)=O MHPUGCYGQWGLJL-UHFFFAOYSA-N 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
• 229910052736 halogen Inorganic materials 0.000 description 10
• 150000002367 halogens Chemical class 0.000 description 10
• AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
• 125000003545 alkoxy group Chemical group 0.000 description 9
• 150000001412 amines Chemical class 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
• 229940098779 methanesulfonic acid Drugs 0.000 description 9
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 9
• 150000007514 bases Chemical class 0.000 description 8
• 125000004432 carbon atom Chemical group C* 0.000 description 8
• 229960002870 gabapentin Drugs 0.000 description 7
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 6
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
• 150000007513 acids Chemical class 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 125000004122 cyclic group Chemical group 0.000 description 6
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
• 229910019142 PO4 Inorganic materials 0.000 description 5
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
• 125000000753 cycloalkyl group Chemical group 0.000 description 5
• 125000001153 fluoro group Chemical group F* 0.000 description 5
• 125000000623 heterocyclic group Chemical group 0.000 description 5
• 150000002431 hydrogen Chemical group 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 150000003254 radicals Chemical class 0.000 description 5
• 229910052717 sulfur Inorganic materials 0.000 description 5
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 229920002261 Corn starch Polymers 0.000 description 4
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 239000008120 corn starch Substances 0.000 description 4
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 4
• 229910052731 fluorine Inorganic materials 0.000 description 4
• 239000011737 fluorine Substances 0.000 description 4
• 239000012458 free base Substances 0.000 description 4
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 230000000704 physical effect Effects 0.000 description 4
• 238000010189 synthetic method Methods 0.000 description 4
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000008238 Muscle Spasticity Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 150000001335 aliphatic alkanes Chemical class 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 150000001768 cations Chemical class 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000007937 lozenge Substances 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 208000018198 spasticity Diseases 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• KKXFMWXZXDUYBF-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCC[C@@H](C)C[C@H](CN)CC(O)=O KKXFMWXZXDUYBF-BDAKNGLRSA-N 0.000 description 2
• LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 2
• FKLQZOOZJOUECB-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-di(propan-2-yl)cyclopentyl]acetic acid Chemical compound CC(C)C1CC(CN)(CC(O)=O)CC1C(C)C FKLQZOOZJOUECB-UHFFFAOYSA-N 0.000 description 2
• HZROAXDCVPLQAB-UHFFFAOYSA-N 2-[3-(aminomethyl)-3-bicyclo[3.1.0]hexanyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC2CC21 HZROAXDCVPLQAB-UHFFFAOYSA-N 0.000 description 2
• BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical compound O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 description 2
• SSXJHQZOHUYEGD-UHFFFAOYSA-N 3-Methoxynobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 SSXJHQZOHUYEGD-UHFFFAOYSA-N 0.000 description 2
• ADEKJVNFIQUGRR-UHFFFAOYSA-N 4h-pyridin-3-one Chemical compound O=C1CC=CN=C1 ADEKJVNFIQUGRR-UHFFFAOYSA-N 0.000 description 2
• BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• FQUACWAUZNAVSB-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclopentyl]methanesulfonamide Chemical compound CC1CCC(CN)(CS(N)(=O)=O)C1 FQUACWAUZNAVSB-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000012154 double-distilled water Substances 0.000 description 2
• UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
• NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 229930182478 glucoside Natural products 0.000 description 2
• 150000008131 glucosides Chemical class 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 125000005553 heteroaryloxy group Chemical group 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 208000021722 neuropathic pain Diseases 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
• 229940100684 pentylamine Drugs 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• SMFBMAIOWXGTNS-UHFFFAOYSA-N pyrazole-3-thione Chemical compound S=C1C=CN=N1 SMFBMAIOWXGTNS-UHFFFAOYSA-N 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical group 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 238000001308 synthesis method Methods 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 229940095064 tartrate Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• IASDTUBNBCYCJG-SFYZADRCSA-N (3r,4r)-3-(azaniumylmethyl)-4,5-dimethylhexanoate Chemical compound CC(C)[C@@H](C)[C@H](CN)CC(O)=O IASDTUBNBCYCJG-SFYZADRCSA-N 0.000 description 1
• IASDTUBNBCYCJG-YUMQZZPRSA-N (3r,4s)-3-(azaniumylmethyl)-4,5-dimethylhexanoate Chemical compound CC(C)[C@H](C)[C@H](CN)CC(O)=O IASDTUBNBCYCJG-YUMQZZPRSA-N 0.000 description 1
• KKXFMWXZXDUYBF-DTWKUNHWSA-N (3r,5s)-3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCC[C@H](C)C[C@@H](CN)CC(O)=O KKXFMWXZXDUYBF-DTWKUNHWSA-N 0.000 description 1
• IASDTUBNBCYCJG-JGVFFNPUSA-N (3s,4s)-3-(aminomethyl)-4,5-dimethylhexanoic acid Chemical compound CC(C)[C@H](C)[C@@H](CN)CC(O)=O IASDTUBNBCYCJG-JGVFFNPUSA-N 0.000 description 1
• BGQCKHBIIZKBJU-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-5,7-dimethyloctanoic acid Chemical compound CC(C)C[C@@H](C)C[C@H](CN)CC(O)=O BGQCKHBIIZKBJU-ZJUUUORDSA-N 0.000 description 1
• ADANSFWHWWMFDU-NEPJUHHUSA-N (3s,5r)-3-(aminomethyl)-5,9-dimethyldecanoic acid Chemical compound CC(C)CCC[C@@H](C)C[C@H](CN)CC(O)=O ADANSFWHWWMFDU-NEPJUHHUSA-N 0.000 description 1
• FEWJHICLKRAPHS-OCCSQVGLSA-N (3s,5r)-3-(aminomethyl)-5-methyl-7-phenylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=CC=C1 FEWJHICLKRAPHS-OCCSQVGLSA-N 0.000 description 1
• XKLLXPMHSPFOQW-HIFRSBDPSA-N (3s,5r)-3-(aminomethyl)-5-methyl-8-phenyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1=CC=CC=C1 XKLLXPMHSPFOQW-HIFRSBDPSA-N 0.000 description 1
• JETOEPZFEWLXBK-MNOVXSKESA-N (3s,5r)-3-(aminomethyl)-5-methyldecanoic acid Chemical compound CCCCC[C@@H](C)C[C@H](CN)CC(O)=O JETOEPZFEWLXBK-MNOVXSKESA-N 0.000 description 1
• IMLWGNYZSUWXIA-OLZOCXBDSA-N (3s,5r)-3-(aminomethyl)-5-methyldodecanoic acid Chemical compound CCCCCCC[C@@H](C)C[C@H](CN)CC(O)=O IMLWGNYZSUWXIA-OLZOCXBDSA-N 0.000 description 1
• SIRQBZJUYVPMIC-SFYZADRCSA-N (3s,5r)-3-(aminomethyl)-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](CN)CC(O)=O SIRQBZJUYVPMIC-SFYZADRCSA-N 0.000 description 1
• LFUPHGVCYOENSK-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-5-methylnon-8-enoic acid Chemical compound C=CCC[C@@H](C)C[C@H](CN)CC(O)=O LFUPHGVCYOENSK-ZJUUUORDSA-N 0.000 description 1
• KUSIIZRBOLFILF-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-5-methylnonanoic acid Chemical compound CCCC[C@@H](C)C[C@H](CN)CC(O)=O KUSIIZRBOLFILF-ZJUUUORDSA-N 0.000 description 1
• HLRPRVFNTZZSHY-NEPJUHHUSA-N (3s,5r)-3-(aminomethyl)-5-methylundecanoic acid Chemical compound CCCCCC[C@@H](C)C[C@H](CN)CC(O)=O HLRPRVFNTZZSHY-NEPJUHHUSA-N 0.000 description 1
• LUHAQNAPMJQCNM-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-6-cyclohexyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CCCCC1 LUHAQNAPMJQCNM-YPMHNXCESA-N 0.000 description 1
• NOTGKXLKLLOOEU-SCZZXKLOSA-N (3s,5r)-3-(aminomethyl)-6-cyclopropyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CC1 NOTGKXLKLLOOEU-SCZZXKLOSA-N 0.000 description 1
• MUDLFVXEGNVOKP-OCCSQVGLSA-N (3s,5r)-3-(aminomethyl)-7-cyclohexyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1CCCCC1 MUDLFVXEGNVOKP-OCCSQVGLSA-N 0.000 description 1
• YBMHFGVRIJZSSK-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-7-cyclopentyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1CCCC1 YBMHFGVRIJZSSK-YPMHNXCESA-N 0.000 description 1
• HOFQYLXJJCNSDJ-SFYZADRCSA-N (3s,5r)-3-(aminomethyl)-8,8,8-trifluoro-5-methyloctanoic acid Chemical compound FC(F)(F)CC[C@@H](C)C[C@H](CN)CC(O)=O HOFQYLXJJCNSDJ-SFYZADRCSA-N 0.000 description 1
• JHCIIQNMXAQHQC-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-8-cyclobutyl-5-methyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1CCC1 JHCIIQNMXAQHQC-YPMHNXCESA-N 0.000 description 1
• CREXEHWDFHWRIL-HIFRSBDPSA-N (3s,5r)-3-(aminomethyl)-8-cyclohexyl-5-methyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1CCCCC1 CREXEHWDFHWRIL-HIFRSBDPSA-N 0.000 description 1
• LGPVGEYDVBVKIW-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-8-fluoro-5-methyloctanoic acid Chemical compound FCCC[C@@H](C)C[C@H](CN)CC(O)=O LGPVGEYDVBVKIW-BDAKNGLRSA-N 0.000 description 1
• IYMWWHAMHAYMGK-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-9-fluoro-5-methylnonanoic acid Chemical compound FCCCC[C@@H](C)C[C@H](CN)CC(O)=O IYMWWHAMHAYMGK-ZJUUUORDSA-N 0.000 description 1
• MYHCDXIFXKZNNJ-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-5-(2-fluoroethoxy)hexanoic acid Chemical compound FCCO[C@@H](C)C[C@H](CN)CC(O)=O MYHCDXIFXKZNNJ-YUMQZZPRSA-N 0.000 description 1
• LUTANLWSGGTECK-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-5-(3,3,3-trifluoropropoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OCCC(F)(F)F LUTANLWSGGTECK-YUMQZZPRSA-N 0.000 description 1
• CQARKITVLVJYGA-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(3-fluorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC(F)=C1 CQARKITVLVJYGA-UWVGGRQHSA-N 0.000 description 1
• LCTKKGWISDWDSR-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-(3-methoxyphenoxy)hexanoic acid Chemical compound COC1=CC=CC(O[C@@H](C)C[C@H](CN)CC(O)=O)=C1 LCTKKGWISDWDSR-QWRGUYRKSA-N 0.000 description 1
• OGJYFMMWUJZBAA-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(3-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC([N+]([O-])=O)=C1 OGJYFMMWUJZBAA-UWVGGRQHSA-N 0.000 description 1
• NHOXILWDZJCMST-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(4-chlorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=C(Cl)C=C1 NHOXILWDZJCMST-UWVGGRQHSA-N 0.000 description 1
• LNMPASBDSUFMIR-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(4-fluorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=C(F)C=C1 LNMPASBDSUFMIR-UWVGGRQHSA-N 0.000 description 1
• JDDJTUPXDBEZQR-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(4-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=C([N+]([O-])=O)C=C1 JDDJTUPXDBEZQR-UWVGGRQHSA-N 0.000 description 1
• PNIDULZEBPPAHE-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-5-(fluoromethoxy)hexanoic acid Chemical compound FCO[C@@H](C)C[C@H](CN)CC(O)=O PNIDULZEBPPAHE-BQBZGAKWSA-N 0.000 description 1
• XSZFKKIBBCFNRZ-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-[(2-methylpropan-2-yl)oxy]hexanoic acid Chemical compound CC(C)(C)O[C@@H](C)C[C@H](CN)CC(O)=O XSZFKKIBBCFNRZ-IUCAKERBSA-N 0.000 description 1
• QIVMNCBZDTZSSL-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-cyclohexylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)C1CCCCC1 QIVMNCBZDTZSSL-QWRGUYRKSA-N 0.000 description 1
• SCUJBZYQUHOYMH-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-cyclopentylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)C1CCCC1 SCUJBZYQUHOYMH-UWVGGRQHSA-N 0.000 description 1
• KPXGGTAOFKPJCB-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-5-cyclopropylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)C1CC1 KPXGGTAOFKPJCB-YUMQZZPRSA-N 0.000 description 1
• ZXQGVLZCFOPLIL-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-5-methoxyhexanoic acid Chemical compound CO[C@@H](C)C[C@H](CN)CC(O)=O ZXQGVLZCFOPLIL-BQBZGAKWSA-N 0.000 description 1
• JBBFMHZVKGOWPT-YPMHNXCESA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-phenylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC=C1 JBBFMHZVKGOWPT-YPMHNXCESA-N 0.000 description 1
• BEYSDHKTOVCIOB-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-propoxyhexanoic acid Chemical compound CCCOC[C@@H](C)C[C@H](CN)CC(O)=O BEYSDHKTOVCIOB-UWVGGRQHSA-N 0.000 description 1
• MYAOGFDZMOXKAG-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-phenoxyhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC=C1 MYAOGFDZMOXKAG-QWRGUYRKSA-N 0.000 description 1
• HBKQWQFIUGDJOB-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-propan-2-yloxyhexanoic acid Chemical compound CC(C)O[C@@H](C)C[C@H](CN)CC(O)=O HBKQWQFIUGDJOB-IUCAKERBSA-N 0.000 description 1
• AMBOZTYDXCXROW-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-propoxyhexanoic acid Chemical compound CCCO[C@@H](C)C[C@H](CN)CC(O)=O AMBOZTYDXCXROW-IUCAKERBSA-N 0.000 description 1
• ZVAKZSCJKNCURF-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(2-chlorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC=C1Cl ZVAKZSCJKNCURF-QWRGUYRKSA-N 0.000 description 1
• BDBBMYYIQJOZRO-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(2-fluorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC=C1F BDBBMYYIQJOZRO-QWRGUYRKSA-N 0.000 description 1
• RXUNPZIYFFDPIM-RYUDHWBXSA-N (3s,5s)-3-(aminomethyl)-6-(2-methoxyphenyl)-5-methylhexanoic acid Chemical compound COC1=CC=CC=C1C[C@@H](C)C[C@H](CN)CC(O)=O RXUNPZIYFFDPIM-RYUDHWBXSA-N 0.000 description 1
• BNSXDZMADNOZMO-PWSUYJOCSA-N (3s,5s)-3-(aminomethyl)-6-(4-fluorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=C(F)C=C1 BNSXDZMADNOZMO-PWSUYJOCSA-N 0.000 description 1
• PQJCGTNFSFNAGC-YPMHNXCESA-N (3s,5s)-3-(aminomethyl)-6-(4-methoxyphenyl)-5-methylhexanoic acid Chemical compound COC1=CC=C(C[C@@H](C)C[C@H](CN)CC(O)=O)C=C1 PQJCGTNFSFNAGC-YPMHNXCESA-N 0.000 description 1
• MLTLRMPTBXSGIZ-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-6-ethoxy-5-methylhexanoic acid Chemical compound CCOC[C@@H](C)C[C@H](CN)CC(O)=O MLTLRMPTBXSGIZ-IUCAKERBSA-N 0.000 description 1
• JAKCHAABXQZLJL-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-7,7,7-trifluoro-5-methylheptanoic acid Chemical compound FC(F)(F)C[C@@H](C)C[C@H](CN)CC(O)=O JAKCHAABXQZLJL-BQBZGAKWSA-N 0.000 description 1
• GEYGHNUUWOVRDW-SFYZADRCSA-N (3s,5s)-3-(aminomethyl)-7-fluoro-5-methylheptanoic acid Chemical compound FCC[C@@H](C)C[C@H](CN)CC(O)=O GEYGHNUUWOVRDW-SFYZADRCSA-N 0.000 description 1
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
• WZHKDGJSXCTSCK-FNORWQNLSA-N (E)-Hept-3-ene Chemical compound CCC\C=C\CC WZHKDGJSXCTSCK-FNORWQNLSA-N 0.000 description 1
• VVQCRZGVHVDBMB-OKWQPMOJSA-N (e,3s,5r)-3-(aminomethyl)-5-methylnon-7-enoic acid Chemical compound C\C=C\C[C@@H](C)C[C@H](CN)CC(O)=O VVQCRZGVHVDBMB-OKWQPMOJSA-N 0.000 description 1
• HEHWAGOHHVUWGC-BKIAHZASSA-N (e,3s,5s)-3-(aminomethyl)-5-methyloct-6-enoic acid Chemical compound C\C=C\[C@@H](C)C[C@H](CN)CC(O)=O HEHWAGOHHVUWGC-BKIAHZASSA-N 0.000 description 1
• JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• YCNOCKHKHPIFAG-UHFFFAOYSA-N 2,5-dimethylnonanoic acid Chemical compound CC(C(=O)O)CCC(CCCC)C YCNOCKHKHPIFAG-UHFFFAOYSA-N 0.000 description 1
• WYBWTBNDYNZFPU-UHFFFAOYSA-N 2-(3-nitrophenoxy)hexanoic acid Chemical compound [N+](=O)([O-])C=1C=C(OC(C(=O)O)CCCC)C=CC=1 WYBWTBNDYNZFPU-UHFFFAOYSA-N 0.000 description 1
• ZHRGCNDKSWYZNL-UHFFFAOYSA-N 2-(4-nitrophenoxy)hexanoic acid Chemical compound CCCCC(C(O)=O)OC1=CC=C([N+]([O-])=O)C=C1 ZHRGCNDKSWYZNL-UHFFFAOYSA-N 0.000 description 1
• CBUFFLKXHMQFEJ-UHFFFAOYSA-N 2-(aminomethyl)hexanoic acid Chemical compound CCCCC(CN)C(O)=O CBUFFLKXHMQFEJ-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• OPAXRDNEIABTQI-VIFPVBQESA-N 2-[(1r)-1-(aminomethyl)-2,2-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC[C@@]1(CN)CC(O)=O OPAXRDNEIABTQI-VIFPVBQESA-N 0.000 description 1
• DNHPJOLWCOXHOV-SNVBAGLBSA-N 2-[(1s)-1-(aminomethyl)-2,2-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC[C@]1(CN)CC(O)=O DNHPJOLWCOXHOV-SNVBAGLBSA-N 0.000 description 1
• IUVMAUQEZFTTFB-HTQZYQBOSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound C[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C IUVMAUQEZFTTFB-HTQZYQBOSA-N 0.000 description 1
• BHQDRZBQUNHTBG-ROUUACIJSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-diphenylcyclopentyl]acetic acid Chemical compound C1([C@H]2[C@@H](CC(C2)(CC(O)=O)CN)C=2C=CC=CC=2)=CC=CC=C1 BHQDRZBQUNHTBG-ROUUACIJSA-N 0.000 description 1
• KOPGUPUTANQKJY-UWVGGRQHSA-N 2-[(3s,4s)-1-(aminomethyl)-3,4-diethylcyclopentyl]acetic acid Chemical compound CC[C@H]1CC(CN)(CC(O)=O)C[C@@H]1CC KOPGUPUTANQKJY-UWVGGRQHSA-N 0.000 description 1
• BHQDRZBQUNHTBG-QZTJIDSGSA-N 2-[(3s,4s)-1-(aminomethyl)-3,4-diphenylcyclopentyl]acetic acid Chemical compound C1([C@@H]2[C@H](CC(C2)(CC(O)=O)CN)C=2C=CC=CC=2)=CC=CC=C1 BHQDRZBQUNHTBG-QZTJIDSGSA-N 0.000 description 1
• ZKPYVRKWQDIKJF-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,3,3,4,4-hexamethylcyclobutyl]acetic acid Chemical compound CC1(C)C(C)(C)C(CN)(CC(O)=O)C1(C)C ZKPYVRKWQDIKJF-UHFFFAOYSA-N 0.000 description 1
• FLNCTXNXKXKYGH-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3,4,4-tetramethylcyclopentyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)CC1(C)C FLNCTXNXKXKYGH-UHFFFAOYSA-N 0.000 description 1
• SRLZVTNHASZZSM-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dibenzylcyclobutyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 SRLZVTNHASZZSM-UHFFFAOYSA-N 0.000 description 1
• XEXRZUKGFDRWLE-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)C1 XEXRZUKGFDRWLE-UHFFFAOYSA-N 0.000 description 1
• CYOHDPOYWOPSRK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-ditert-butylcyclobutyl]acetic acid Chemical compound CC(C)(C)C1(C(C)(C)C)CC(CN)(CC(O)=O)C1 CYOHDPOYWOPSRK-UHFFFAOYSA-N 0.000 description 1
• KOPGUPUTANQKJY-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-diethylcyclopentyl]acetic acid Chemical compound CCC1CC(CN)(CC(O)=O)CC1CC KOPGUPUTANQKJY-UHFFFAOYSA-N 0.000 description 1
• UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical compound CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 description 1
• ONKWZNBXHSMMDK-UHFFFAOYSA-N 2-[2-(aminomethyl)-1,3,3a,4,5,6,7,7a-octahydroinden-2-yl]acetic acid Chemical compound C1CCCC2CC(CN)(CC(O)=O)CC21 ONKWZNBXHSMMDK-UHFFFAOYSA-N 0.000 description 1
• NDDZVQRQVFTNSN-UHFFFAOYSA-N 2-[3-(aminomethyl)-3-bicyclo[3.2.0]heptanyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC2CCC21 NDDZVQRQVFTNSN-UHFFFAOYSA-N 0.000 description 1
• 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 description 1
• CLAQMWDLICXNBF-UHFFFAOYSA-N 2-methyl-6-phenoxyhexanoic acid Chemical compound OC(=O)C(C)CCCCOC1=CC=CC=C1 CLAQMWDLICXNBF-UHFFFAOYSA-N 0.000 description 1
• FFOTVQGMOMHDRN-UHFFFAOYSA-N 2-nitro-2-phenoxyhexanoic acid Chemical compound CCCCC([N+]([O-])=O)(C(O)=O)OC1=CC=CC=C1 FFOTVQGMOMHDRN-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• YCYMCMYLORLIJX-UHFFFAOYSA-N 2-propyloctanoic acid Chemical compound CCCCCCC(C(O)=O)CCC YCYMCMYLORLIJX-UHFFFAOYSA-N 0.000 description 1
• UVUQVKDHNYUOJX-UHFFFAOYSA-N 2h-oxadiazol-5-one;hydrochloride Chemical compound Cl.O=C1C=NNO1 UVUQVKDHNYUOJX-UHFFFAOYSA-N 0.000 description 1
• WYNCISGDELJLFS-UHFFFAOYSA-N 2h-oxadiazole-5-thione Chemical compound S=C1C=NNO1 WYNCISGDELJLFS-UHFFFAOYSA-N 0.000 description 1
• AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
• KDCBMCJRMVNJSC-UHFFFAOYSA-N 3-(aminomethyl)-4-ethyl-5-methylhexanoic acid Chemical compound CCC(C(C)C)C(CN)CC(O)=O KDCBMCJRMVNJSC-UHFFFAOYSA-N 0.000 description 1
• MANPXHGDIYSTEN-UHFFFAOYSA-N 3-(aminomethyl)-4-propan-2-ylheptanoic acid Chemical compound CCCC(C(C)C)C(CN)CC(O)=O MANPXHGDIYSTEN-UHFFFAOYSA-N 0.000 description 1
• XLNITVUBTMJFSS-UHFFFAOYSA-N 3-(aminomethyl)-4-propan-2-ylnonanoic acid Chemical compound CCCCCC(C(C)C)C(CN)CC(O)=O XLNITVUBTMJFSS-UHFFFAOYSA-N 0.000 description 1
• MZXNUBDMHKYIDC-UHFFFAOYSA-N 3-(aminomethyl)-5-(2-chlorophenyl)hexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1=CC=CC=C1Cl MZXNUBDMHKYIDC-UHFFFAOYSA-N 0.000 description 1
• AVDPWOUCNFZVNY-UHFFFAOYSA-N 3-(aminomethyl)-5-(2-methoxyphenyl)hexanoic acid Chemical compound COC1=CC=CC=C1C(C)CC(CN)CC(O)=O AVDPWOUCNFZVNY-UHFFFAOYSA-N 0.000 description 1
• YODGVKRANQWMHX-UHFFFAOYSA-N 3-(aminomethyl)-5-(3-chlorophenyl)hexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1=CC=CC(Cl)=C1 YODGVKRANQWMHX-UHFFFAOYSA-N 0.000 description 1
• OILXZDNEKPMMNR-UHFFFAOYSA-N 3-(aminomethyl)-5-(4-methoxyphenyl)hexanoic acid Chemical compound COC1=CC=C(C(C)CC(CN)CC(O)=O)C=C1 OILXZDNEKPMMNR-UHFFFAOYSA-N 0.000 description 1
• NECOLRNJBIIURC-UHFFFAOYSA-N 3-(aminomethyl)-5-cyclobutylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1CCC1 NECOLRNJBIIURC-UHFFFAOYSA-N 0.000 description 1
• QIVMNCBZDTZSSL-UHFFFAOYSA-N 3-(aminomethyl)-5-cyclohexylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1CCCCC1 QIVMNCBZDTZSSL-UHFFFAOYSA-N 0.000 description 1
• JBBFMHZVKGOWPT-UHFFFAOYSA-N 3-(aminomethyl)-5-methyl-6-phenylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)CC1=CC=CC=C1 JBBFMHZVKGOWPT-UHFFFAOYSA-N 0.000 description 1
• JETOEPZFEWLXBK-UHFFFAOYSA-N 3-(aminomethyl)-5-methyldecanoic acid Chemical compound CCCCCC(C)CC(CN)CC(O)=O JETOEPZFEWLXBK-UHFFFAOYSA-N 0.000 description 1
• TZOKXKRKSNVJGE-UHFFFAOYSA-N 3-(aminomethyl)-5-methyltridecanoic acid Chemical compound CCCCCCCCC(C)CC(CN)CC(O)=O TZOKXKRKSNVJGE-UHFFFAOYSA-N 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
• IASDTUBNBCYCJG-UHFFFAOYSA-N 4-methylpregabalin Chemical compound CC(C)C(C)C(CN)CC(O)=O IASDTUBNBCYCJG-UHFFFAOYSA-N 0.000 description 1
• OJTHHBCWUMTZEY-UHFFFAOYSA-N 5-methyl-heptanoic acid Chemical compound CCC(C)CCCC(O)=O OJTHHBCWUMTZEY-UHFFFAOYSA-N 0.000 description 1
• NBFUWTJYLVDDLQ-UHFFFAOYSA-N 5h-pyren-4-one Chemical compound C1=CC=C2C(=O)CC3=CC=CC4=CC=C1C2=C34 NBFUWTJYLVDDLQ-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
• 239000010754 BS 2869 Class F Substances 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 206010006298 Breast pain Diseases 0.000 description 1
• 208000009079 Bronchial Spasm Diseases 0.000 description 1
• 208000014181 Bronchial disease Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• AUCBFYWBOPGVTI-UHFFFAOYSA-N CC1CC(CN)(CC1C)NS(C)(=O)=O Chemical compound CC1CC(CN)(CC1C)NS(C)(=O)=O AUCBFYWBOPGVTI-UHFFFAOYSA-N 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 241000258920 Chilopoda Species 0.000 description 1
• QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
• FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
• OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 206010011469 Crying Diseases 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 208000006558 Dental Calculus Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 229910052691 Erbium Inorganic materials 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• XSRWMYORWAQSNQ-UHFFFAOYSA-N FNCl Chemical compound FNCl XSRWMYORWAQSNQ-UHFFFAOYSA-N 0.000 description 1
• 208000027601 Inner ear disease Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 208000006662 Mastodynia Diseases 0.000 description 1
• 201000005505 Measles Diseases 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 208000000060 Migraine with aura Diseases 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 206010033649 Pancreatitis chronic Diseases 0.000 description 1
• 241000282376 Panthera tigris Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 206010073211 Postural tremor Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 206010039509 Scab Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 208000013200 Stress disease Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• NFEYNHNJNQQPRK-VIFPVBQESA-N [(1S)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methyl dihydrogen phosphate Chemical compound NC[C@]1(CC(CC1)(C)C)COP(O)(O)=O NFEYNHNJNQQPRK-VIFPVBQESA-N 0.000 description 1
• WPGAQKHDJXNUEM-SECBINFHSA-N [(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonic acid Chemical compound CC1(C)CC[C@@](CN)(CS(O)(=O)=O)C1 WPGAQKHDJXNUEM-SECBINFHSA-N 0.000 description 1
• WPGAQKHDJXNUEM-VIFPVBQESA-N [(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonic acid Chemical compound CC1(C)CC[C@](CN)(CS(O)(=O)=O)C1 WPGAQKHDJXNUEM-VIFPVBQESA-N 0.000 description 1
• OQVYAGYPTAPIDD-HTQZYQBOSA-N [(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methanesulfonic acid Chemical compound C[C@@H]1CC(CN)(CS(O)(=O)=O)C[C@H]1C OQVYAGYPTAPIDD-HTQZYQBOSA-N 0.000 description 1
• ULSOITPPNZYVQD-UHFFFAOYSA-N [1-(aminomethyl)-3,3-dimethylcyclobutyl]methyl dihydrogen phosphate Chemical compound NCC1(CC(C1)(C)C)COP(O)(O)=O ULSOITPPNZYVQD-UHFFFAOYSA-N 0.000 description 1
• JVTOSAVRBRSNKM-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclohexyl]methanesulfonamide Chemical compound CC1CCCC(CN)(CS(N)(=O)=O)C1 JVTOSAVRBRSNKM-UHFFFAOYSA-N 0.000 description 1
• GTSLDHDWPQDRMR-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1(CN)CCCCC1 GTSLDHDWPQDRMR-UHFFFAOYSA-N 0.000 description 1
• WRWYGOVGIGCDLE-UHFFFAOYSA-N [O]c1ccccc1F Chemical group [O]c1ccccc1F WRWYGOVGIGCDLE-UHFFFAOYSA-N 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
• RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 208000012826 adjustment disease Diseases 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000003342 alkenyl group Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 150000001409 amidines Chemical group 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 210000000576 arachnoid Anatomy 0.000 description 1
• 150000001483 arginine derivatives Chemical class 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
• 208000025748 atypical depressive disease Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 239000007767 bonding agent Substances 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 229940097217 cardiac glycoside Drugs 0.000 description 1
• 239000002368 cardiac glycoside Substances 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 206010008129 cerebral palsy Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• MMIVZWZHLDUCKH-UHFFFAOYSA-N chloromethane;chloromethylbenzene Chemical compound ClC.ClCC1=CC=CC=C1 MMIVZWZHLDUCKH-UHFFFAOYSA-N 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 238000005260 corrosion Methods 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 208000002925 dental caries Diseases 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
• 238000003255 drug test Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 238000013171 endarterectomy Methods 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000007941 film coated tablet Substances 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 238000003682 fluorination reaction Methods 0.000 description 1
• WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 238000002309 gasification Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000000423 heterosexual effect Effects 0.000 description 1
• VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
• FYAQQULBLMNGAH-UHFFFAOYSA-N hexane-1-sulfonic acid Chemical compound CCCCCCS(O)(=O)=O FYAQQULBLMNGAH-UHFFFAOYSA-N 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
• 229940071870 hydroiodic acid Drugs 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 210000001937 intercostal nerve Anatomy 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical compound [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000011812 mixed powder Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 230000002151 myoclonic effect Effects 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 229940072228 neurontin Drugs 0.000 description 1
• 208000015238 neurotic disease Diseases 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
• 125000003431 oxalo group Chemical group 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 208000021090 palsy Diseases 0.000 description 1
• 230000000803 paradoxical effect Effects 0.000 description 1
• 208000013667 paroxysmal dyskinesia Diseases 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 229960005152 pentetrazol Drugs 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 239000008055 phosphate buffer solution Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 230000008565 psychomotor impairment Effects 0.000 description 1
• 238000005086 pumping Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 230000008653 root damage Effects 0.000 description 1
• 230000036280 sedation Effects 0.000 description 1
• DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 235000014347 soups Nutrition 0.000 description 1
• 229940083466 soybean lecithin Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 229930002534 steroid glycoside Natural products 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
• 231100000736 substance abuse Toxicity 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
• ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
• 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1